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Background: The available pharmacokinetic data on anti-tubercular drugs in children raises the concern of suboptimal
plasma concentrations attained when doses extrapolated from adult studies are used. Also, there is lack of consensus
regarding the effect of malnutrition on pharmacokinetics of anti-tubercular drugs in children. We conducted this study
with the aims of determining the plasma concentrations of isoniazid, rifampicin, pyrazinamide and ethambutol
achieved with different dosage of the anti-tubercular drugs so as to provide supportive evidence to the revised
dosages and to evaluate the effects of malnutrition on the pharmacokinetics of these drugs in children. We also
attempted to correlate the plasma concentrations of these drugs with clinical outcome of therapy.
Method: Prospective drug estimation study was conducted in two groups of children, age 6 months to 15 years, with
tuberculosis, with or without severe malnutrition, receiving different dosage of daily anti- tubercular therapy. The
dosage (range) of isoniazid was 5 (4-6) and 10 (7-15) mg/kg in the two groups, respectively, that of rifampicin-10 (8–12)
and 15 (10–12) mg/kg, respectively, both the groups received same dose of pyrazinamide (30–35 mg/kg) and
ethambutol (20–25 mg/kg). All four drugs were simultaneously estimated by liquid chromatography-mass
spectrometry (LC-MS/MS).
Results and conclusion: The median (IQR) Cmax of isoniazid increased significantly from 0.6 (0.3,1.2) μg/mL to 3.4
(1.8, 5.0) μg/mL with increase in the dose. Plasma rifampicin concentrations increased only marginally on increasing the
dose [median (IQR) Cmax: 10.4 (7.2, 13.9) μg/mL vs. 12.0 (6.1, 24.3) μg/mL, p = 0.08]. For ethambutol, 55.9% of the
children had inadequate 2-hour concentrations. Two-hour plasma concentrations of at least one drug were low in 59
(92.2%) and 54 (85.7%) children in the two dosing regimen, respectively. We did not observe any effect of malnutrition
on pharmacokinetic parameters of the drugs studied. We did not observe an association between low plasma drug
concentrations and poor outcome. We may have to be cautious while increasing the doses and strive to asses other
factors influencing the drug concentrations and treatment outcomes in children.
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Escalating reports of treatment failure and emergence
of resistance worldwide with the use of standard short
course chemotherapy for tuberculosis (TB) reflect a
worrying trend. In 2013, 20% of those previously treated
for tuberculosis had multidrug resistance [1]. Sub-
therapeutic plasma concentrations of anti-tubercular
drugs in adults have been implicated as one of the causes
of treatment failure and emergence of resistance [2-5].* Correspondence: rakesh_lodha@hotmail.com
1Department of Pediatrics, All India Institute of Medical Sciences, New Delhi,
India
Full list of author information is available at the end of the article
© 2015 Mukherjee et al.; licensee BioMed Cen
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.The pharmacokinetic data on anti-tubercular drugs in
children raises the concern of suboptimal plasma con-
centrations attained when the same mg/kg dose used in
adults is extrapolated to children [6-11]. Children ab-
sorb, metabolize and eliminate these drugs in a different
manner than adults. It is extrapolation of adult doses to
children, without correctly accounting for the changes in
pharmacokinetics with growth and maturation, etc. that
may lead to incorrect dosing in children. Though isonia-
zid has been studied extensively, there are relatively
fewer studies on rifampicin, pyrazinamide and etham-
butol in children. These studies vary in the type of assay
used for measurement of drug concentrations, sampling
schedule adopted, type of anti-tubercular therapy (ATT)tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Recommended doses of first-line anti-TB drugs
for children




Isoniazid 5 (4–6) 10 (7–15)
Rifampicin 10 (8–12) 15 (10–20)
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tions used–fixed dose combination or separate single
formulations. These variations make direct comparison
of data obtained from the available pharmacokinetic
studies in children challenging.
After a review of available data, WHO has recom-
mended revision of the doses of isoniazid, rifampicin and
pyrazinamide in children, with an intent to reach the usu-
ally recommended targets for adults [12].
Malnutrition is associated with various processes in the
body which may influence the pharmacokinetics of the
anti-tubercular drugs - malabsorption, as well as enteric in-
fections, deranged drug metabolizing enzymes, alteration
in the protein binding of drugs, an increased or decreased
renal clearance, and changes in the body composition
(lower fat and lean body mass) [13,14]. If patients absorb
only portions of their drug regimen, effectively they are ex-
posed to a regimen of fewer anti-tubercular drugs or even
monotherapy leading to the selection of resistant strains
[13-15]. The effect of malnutrition on pharmacokinetics of
anti-tubercular drugs in children has not been very well ex-
plored. The few studies which are available lack consensus.
In a recently published study, Ramachandran et al. re-
ported on the pharmacokinetics of three anti-tubercular
drugs in Indian children using intermittent regimen and
observed that the drug concentrations were affected by
age, malnutrition and INH acetylator phenotype [16]. This
study was planned to assess the plasma concentrations of
isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA) and
ethambutol (EMB) achieved in children. The effect of dif-
ferent doses on the drug concentrations was evaluated for
RIF and INH, only; while the effect of malnutrition was ex-
plored for all 4 drugs. An attempt was also made to correl-
ate plasma concentrations of the said drugs with clinical
outcome of therapy.
Methods
This prospective study was carried out in a tertiary care
hospital in New Delhi, India from 2009 to 2012. Children
were screened and then enrolled from TB clinic services
of the Department of Pediatrics, All India Institute of
Medical Sciences, New Delhi. The study was approved by
the Ethics Committee of the All India Institute of Medical
Sciences. Written informed consent was taken from par-
ents/guardians, assent was taken from children above
seven years of age.
Children 6 months- 15 years age, who were newly diag-
nosed to have tuberculosis (pulmonary or extrapulmon-
ary) and administered Category I ATT, were eligible for
the study. Children with known HIV infection or any his-
tory, symptoms or signs suggestive of HIV infection, with
poor general condition with high chances of mortality,
known hepatic (transaminases > 5 times the upper normal
limit) or renal dysfunction (creatinine > 0.7 mg/dL),adherence to ATT < 80% in two weeks preceding the
pharmacokinetic session, those with chronic diarrhea/
steatorrhea at the time of enrollment, and those with ab-
dominal tuberculosis were excluded.
In the initial part of the study (2009–2011), children
received the standard dosing schedule of ATT. Subse-
quently the second group was enrolled who received the
revised dosing schedule of INH and RIF (Table 1). The
national guidelines [17] were revised in favor of higher
doses of isoniazid and rifampicin in 2012. However, even
till date the same has not been operationalized. The en-
rollment in the standard dosing group was continued in
view of the fact that data on Indian children generated
from well-planned pharmacokinetic study were lacking
and the findings of the current study would provide more
robust evidence in support of these dose changes. Each of
these groups had two subgroups: children without severe
malnutrition and children with severe malnutrition. For
the purpose of this study, severe malnutrition was defined
in children upto five years of age as weight for height/
length < 70% of expected [expected being 50thcentile of
CDC weight for height/length curve] and in children
above five years as body mass index (BMI) for age < 5th
percentile [18,19]. The definition of malnutrition that was
used in clinical practice at the beginning of the study was
used in the proposal and for sake of uniformity was not
changed later on.
Diagnosis of tuberculosis was established according to
the standard guidelines [20]. Confirmation of Mycobacter-
ium tuberculosis by Ziehl Neelsen staining and MGIT-
960®culture system was attempted from any biological
sample as feasible.
On enrollment a detailed history was taken, physical
examination and anthropometric assessment (weight,
height) were carried out.
Treatment
Category based anti-tubercular therapy as recom-
mended by Revised National Tuberculosis Control Pro-
gram (RNTCP) was administered [21], daily therapy
was followed - four drugs (isoniazid, rifampicin, pyrazi-
namide and ethambutol) in intensive phase for first two
months followed by two drugs (isoniazid and rifampi-
cin) for four months during maintenance phase. This is
considered as category I as per RNTCP. For children
continuing to have clinical symptoms or radiological
findings attributable to tuberculosis at the end of
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one month. The maintenance phase was extended for
10 months in cases of osteo-articular TB.
In the first group, dosages used were INH: 5 (4-6) mg/
kg, RIF: 10 (8–12) mg/kg, PZA: 30–35 mg/kg, EMB: 20–
25 mg/kg (Table 1) [21,22]. Fixed dose combinations
(Isoniazid-50 mg, Rifampicin-100 mg, Pyrazinamide-
300 mg per dispersible tablet) and ethambutol (200 mg)
tablets were procured from Macleods Pharmaceuticals
Limited, Mumbai, India.
In the second group, isoniazid and rifampicin were ad-
ministered according to the revised dosage recom-
mended by WHO- INH: 10 (7–15) mg/kg, RIF: 15 (10–
20) mg/kg, PZA: 30-35 mg/kg, EMB: 20–25 mg/kg
(Table 1) [12]. Fixed dose combinations (Isoniazid-
75 mg, Rifampicin-100 mg, Pyrazinamide- 250 mg per
dispersible tablet, Concept Pharmaceutical Limited,
India) were used along with separate tablets for etham-
butol (200 mg), same as the first group (see Additional
file 1 for tables describing the weight band based dosing
for both groups of children).
Depending on their ability, children either swallowed
the tablets with minimal water or the dispersible medi-
cines were dissolved in a teaspoon of water and adminis-
tered under supervision of study personnel.
Blood sampling
The samples for pharmacokinetic study were collected
14 days (upto 30 days) after starting ATT in all children.
Pharmacokinetic sessions were planned such that the
first sampling was done at least 24 hours from the last
dose of ATT. On the day of scheduled blood sampling,
enrolled children were asked to report in empty stomach
in the morning to the pediatric services. The first blood
sample (0 hour) was collected before administration of
any drug. Immediately following the 0 hour sample, the
medicines based on body weight measured at that point
was administered. Next three point samplings at 1, 2
and 4 hours were done, calculating from the time of in-
take of drugs. Breakfast was allowed one hour after the
drug, after collecting the blood sample at that point. At
each time point, 0.5 mL blood was collected in polypro-
pylene tube wrapped in aluminum foil, containing EDTA
and sodium ascorbate and kept at 4°C. Plasma was sepa-
rated soon after and stored at −80°C till further analysis.
The same schedule was followed in both the dosage
groups.
Measurement of anti-tubercular drug concentrations in
plasma by liquid chromatography-mass spectrometry
(LC-MS/MS)
We used Ultra High Performance Liquid Chromato-
graphic system (UHPLC, Thermo Surveyor system, CITY,
USA) coupled with a triple quadrupole mass spectrometer,API-4000 QTrap equipped with Turbo Ion Spray ionization
(ESI) source (MDS SCIEX, Applied Biosystems, USA), op-
erated in positive mode for separation and detection of ana-
lytes. Standards for isoniazid, rifampicin, pyrazinamide,
ethambutol and 6- amino-nicotinic acid (6-ANA) were pro-
cured from Sigma-Aldrich Ltd, India, having purity greater
than 99%. Standard for acetyl isoniazid was synthesized in-
house [23]. Linear calibration curves for isoniazid, rifampi-
cin, pyrazinamide, ethambutol and acetyl isoniazid were
prepared separately, keeping r > =0.99. The LLOD (lower
limit of detection) and LLOQ (lower limit of quantification)
for each of the analytes were: INH= 0.011 μg/mL and
0.014 μg/mL, RIF = 0.025 μg/mL and 0.031 μg/mL, PZA =
0.054 μg/mL and 0.547 μg/mL, ETB = 0.015 μg/mL and
0.018 μg/mL. Spiked sample calibration curve was sub-
jected to inter-day and intraday variations’ analysis. The cal-
culated coefficient of variation for their inter-day and
intraday variation was <10%.
Pharmacokinetic parameters
The pharmacokinetic parameters of Cmax (maximum
plasma concentration achieved) and Tmax (time taken to
achieve the maximum concentration) were determined by
visual inspection of the data. Area under curve from 0–4
hours (AUC0–4) was calculated by the linear trapezoidal
rule. The actual values for plasma concentrations at vari-
ous time points as determined by LCMS/MS assay were
considered for analysis.
The lower cut-offs for acceptable two hour plasma con-
centration or the usually targeted concentrations in adults
were as follows: Isoniazid <3 μg/mL, rifampicin <8 μg/mL,
pyrazinamide <20 μg/mL and ethambutol <2 μg/mL [24].
Children with acetyl-isoniazid/isoniazid ratio at 4 hours
of less than 1.0 were considered as slow acetylators [25].
Follow-up
The children were regularly followed-up till the completion
of ATT and six months thereafter. Outcome of treatment
was recorded in children for whom data for at least six
months of ATT was available. Any child for whom change
or extension of ATT regime was required or death oc-
curred, was considered to be having a poor outcome. Good
outcome was defined as completion of ATT within sched-
uled time. Any need for re-introduction of ATT after stop-
ping therapy within the one year follow-up time period
was defined as relapse. Category II ATT is defined as
2 months of INH + RIF+ EMB + PZA + injectable strepto-
mycin, followed by one month of INH + RIF+ EMB +
PZA, followed by 5 months of INH + RIF+ EMB [21].
Sample size
Considering the inadequacy of data from well-designed
studies in children in context to influence of malnutri-
tion on pharmacokinetics of anti-tubercular drugs, a
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Statistical analysis
Data were managed on MS Excel/Access softwares (ver-
sion 2007) and analyzed using Stata 12.0 software (Stata-
Corp, College Station, TX, USA). The significance of the
differences in the categorical variables were assessed
using chi-square or Fisher’s exact test and that of con-
tinuous variables using student’s t test/Wilcoxon rank-
sum test as appropriate. A multivariate linear regression
was done to predict the factors affecting 2 hour INH
concentration, Cmax and AUC0–4 of INH and RIF, with
dose of INH and RIF in mg/kg, age, gender, weight for
age and height for age z score as covariates. In case of
INH, acetylator status was also included in the model.
A bivariate analysis (Wilcoxon ranksum test was used
for the continuous variables, as the distribution was non-
normal, whereas for categorical variables, chi-squared test
was used) was carried out to identify the factors influen-
cing the outcome of ATT in the enrolled children for
whom follow-up data of at least six months were available.
A multivariate logistic regression model was used to pre-
dict the factors affecting outcome with 2-hour plasmaTable 2 Baseline characteristics of children receiving standard
Characteristics Standard dosage, n = 64
Without severe
malnutrition, n = 32
With sever
malnutritio
Age, mean (SD), months 97.2 (43.9) 105.9 (43.1)
No of children, n (%)
<2 years of age 1 (3.1) 0
2-5 years 6 (18.8) 1 (3.1)
>5 years 25 (78.1) 31 (96.9)
Boys, n (%) 15 (46.9) 15 (46.9)
Received BCG, n (%) 27 (84.4) 21 (65.6)
Weight for age z score,
median (IQR)
−1.5 (−2.1, -0.7) −2.7 (−3.2,
Height for age z score,
median (IQR)
−1.4 (−2.03, 0) −2.5 (−4.2,
Weight for height z score,
median (IQR)
−1.1 (−1.9, -0.7) −1.5 (−1.9,
BMI z score, median (IQR) −0.8 (−1.4, -0.2) −1.7 (−2.5,




18 (56.2) 18 (56.2)
Pleural effusion 4 (12.5) 4 (12.5)
Disseminated 10 (31.3) 10 (31.3)
Osteoarticular 0 0
Peripheral lymphadenopathy 0 0
IQR: interquartile range, SD: standard deviation, AFB: acid fast bacillus, MGIT: Mycobconcentration of INH, RIF, PZA and EMB, age, weight for
age and height for age z score and BCG vaccination status
as covariates.
Weight-for-age (WAZ), height-for-age (HAZ) and
weight-for-height (WHZ) Z scores and BMI z scores
were calculated using the nutritional anthropometry
module of EpiInfo version 5 (Centers for Disease Con-
trol and Prevention, Atlanta), based on the CDC-2000
curves [18].
Results
We enrolled 127 children- 64 received the standard dose
of ATT, whereas 63 received the revised dosage. The
baseline characteristics of the enrolled children are out-
lined in Table 2. The children receiving standard or re-
vised dosage of ATT were comparable in their baseline
characteristics like age, gender, weight for height or BMI
z-scores. All the children received category I ATT. Due
to inadequate volume, one sample at 1 hour, 2 samples
each at 2 and 4 hour time-points could not be assayed.
Isoniazid
The median Cmax and 2-hour levels, which were below
usually targeted concentrations with the initial doses,and revised dosage of anti-tubercular therapy
Revised dosage, n = 63
e
n, n = 32
Without severe
malnutrition, n = 37
With severe
malnutrition, n = 26
126.5 (28.4) 91.3 (38.6)
1 (2.7) 1 (3.8)
9 (24.3) 2 (7.7)
27 (73) 23 (88.5)
20 (54.1) 16 (61.5)
24 (77.4) 20 (86.9)
-1.8) −1.3 (−1.7, -0.4) −1.9 (−2.4, -1.4)
-1.6) −1.1 (−1.9, -0.1) −1.3 (−2.1, -0.7)
-1.03) −0.6 (−1.1, -0.2) −1.9 (−2.2, -1.3)
−0.6) −0.7 (−1.2, −0.4) −2.1 (−2.8, -1.8)





13 (35.2) 7 (27)
acterial growth indicator tube, BCG: Bacillus Calmette Guerin.
Mukherjee et al. BMC Infectious Diseases  (2015) 15:126 Page 5 of 11increased significantly after increasing the dose. The
number of children with low 2-hour plasma concentra-
tions was 59 (95.2%) for the standard dose group as
compared to 43 (68.3%) for the revised dose group, p <
0.001 (Table 3). In the group with revised higher dose,
the median Cmax achieved was significantly higher in
children <5 years of age [4.8 (3.8, 5.8) vs. 3.04 (1.6, 4.6)
μg/mL, p = 0.03], whereas no such age wise difference
could be ascertained at a dose of 5 mg/kg. The mean
(SD) dose of INH in children younger than 5 years in
the revised doses group was 12.1 (0.8) mg/kg and 11.2
(0.7) mg/kg for older children.
Acetylator status
The acetylator phenotype was determined in 122 chil-
dren. Fast acetylator phenotype was ascertained in 81.2%
of the children, whereas 18.8% were slow acetylators. In
the group of children receiving standard dosage, 86.7%
(52 children) were fast acetylators and 13.3% (8 children)
were slow acetylators; amongst the severely malnour-
ished children in this group 90% (27 children) were fast
acetylators, whereas amongst the children who were not
severely malnourished 83.3% were fast acetylators. In the
other group receiving revised dosage, 75.8% (47 chil-
dren) were fast acetylators whereas 24.2% (15 children)
were slow acetylators; percentages of fast acetylators
amongst children with or without severe malnutrition in
this group were 84.6% and 69.4%, respectively. In the
first group, the median 2-hour plasma concentration
[1.2 (0.6, 2.9) vs. 0.4 (0.1, 0.7) μg/mL, p = 0.001] as well
as Cmax achieved [1.8 (1.4, 3.4) vs. 0.6 (0.3, 0.9) μg/mL,
p = 0.0001] were higher in slow acetylators as compared
to the fast acetylators. AUC0–4 obtained was also higher
in the slow acetylators [4.5 (3.2, 9.7) vs. 1.2 (0.7, 2.1) μg/
mL*hr, p = 0.0001]. Similarly in the revised doses group,
slow acetylators attained a higher 2-hour concentration
[3.8 (2.7, 5.1) vs. 1.6 (1.1, 2.9), p = 0.003] and Cmax [4.6
(3.4, 7.2) vs. 2.9 (1.5, 4.7), p = 0.007] of INH as compared
to the fast acetylators.Table 3 Pharmacokinetic parameters of isoniazid and rifampi
Parameter Isoniazid
Standard dose, n = 64 Revised dose, n = 6
Dose, mg/kg, mean (SD) 5.6 (0.5) 11.4 (0.8)
2-hour concentration,
μg/mL
0.4 (0.2, 0.8) 2.0 (1.2, 3.7)
Cmax, μg/mL 0.7 (0.3, 1.2) 3.4 (1.8, 5.0)
Tmax, hour 1 (1, 2) 1 (1, 2)
AUC0–4, μg/mL*hr 1.5 (0.8, 2.6) 7.0 (4.4, 11.9)
Low 2-hr concentration*,
n (%)
59 (95.2) 43 (68.3)
Values are expressed as median (IQR) unless specified.
*Low 2-hr concentrations: plasma concentration of isoniazid <3 μg/mL, rifampicin <
Cmax: maximum concentration, Tmax: Time needed to reach the maximum concentraWhen a multivariate linear regression was done, only
lower dose of INH in mg/kg and fast acetylator status
were significantly associated with lower 2-hour INH
concentration, Cmax and AUC0–4 after adjusting for age,
gender, weight for age and height for age z score.
Rifampicin
The median concentration reached at two hour time-
point and Cmax increased marginally with the increase
in dose, the changes were not statistically significant.
AUC0–4 also increased marginally (p = 0.2). Number of
children with low 2-hour plasma concentration remained
almost unaltered (43.5% vs. 41.3%, p = 0.8) (Table 3).
There was no influence of age on the 2-hour concentra-
tion of RIF at either of the doses. A linear regression
showed that lower 2-hour RIF concentrations, Cmax and
AUC0–4 were significantly associated with only dose in
mg/kg of RIF when adjusted for age, gender, weight for
age and height for age z score.
Pyrazinamide
Dose of pyrazinamide above 30 mg/kg (mean: 35.8, SD:
3.6) resulted in plasma concentrations of the drug above
the acceptable cut-off levels. Only eight (6.4%) children
had low 2-hour plasma levels (Table 4).
Ethambutol
More than half (55.9%) of the children had 2-hour con-
centration lower than the usually targeted levels. Details
are outlined in Table 4.
In the first group, 2-hour plasma concentrations of at
least one drug were low in 59 (92.2%) children. With the
revised doses, 54 (85.7%) children had low 2-hour
plasma concentrations of at least one drug.
Effect of nutritional status on pharmacokinetics of
isoniazid, rifampicin, pyrazinamide and ethambutol
The pharmacokinetic parameters of isoniazid and rifam-
picin in either of the dosing schedules and that ofcin at standard and revised dosage
Rifampicin
3 p value Standard dose, n = 64 Revised dose, n = 63 p value
<0.0001 11.2 (1.0) 15.2 (1.1) <0.0001
<0.0001 8.8 (5.4, 11.9) 9.9 (5.4, 19.9) 0.06
<0.0001 10.4 (7.2, 13.9) 12.0 (6.1, 24.3) 0.08
0.6 1.5 (1, 2) 2 (2, 3) 0.004
<0.0001 28.0 (19.3, 35.5) 30.5 (17.1, 58.9) 0.2
<0.001 27 (43.5) 26 (41.3) 0.79
8 μg/mL at 2 hour post drug time point.
tion, AUC: area under curve.
Table 4 Pharmacokinetic parameters of ethambutol and
pyrazinamide in 127 children
Parameter Ethambutol Pyrazinamide
Dose, mg/kg, mean (SD) 21.7 (2.4) 35.7 (3.6)
2-hour concentration, μg/mL 1.5 (0.6, 3.1) 42.7 (34.9, 52.9)
Cmax, μg/mL 2.1 (1.0, 3.7) 47.8 (39.4, 58.5)
Tmax, hours 2 (1, 2) 2 (1, 2)
AUC0–4, μg/mL*hr 4.8 (2.2, 8.9) 140.5 (117.4, 173.2)
Low 2-hr concentration*, n (%) 71 (55.9) 8 (6.4)
Values are expressed as median (IQR) unless specified.
*Low 2-hr concentration: plasma concentration of ethambutol <2 μg/mL,
pyrazinamide <20 μg/mL at 2 hour post drug time point.
Cmax: maximum concentration, Tmax: Time needed to reach the maximum
concentration, AUC: area under curve.
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number of children with low two hour plasma concen-
tration did not differ in children with or without severe
malnutrition (see Additional file 1).
Treatment response
Evaluation of treatment response at the end of six
months of anti-tubercular therapy were available in 62
children of the first group and 61 children in the second
group receiving revised dosage of ATT.
In the first group, category II ATT had to be started
due to non-resolution of symptoms or radiological find-
ings in 4 (6.2%) children, 2nd line ATT was started in
one (1.6%) child. One (1.6%) child had relapse of disease
after completion of therapy and was administered cat-
egory II treatment. Hepatitis developed in 2 (3.2%) chil-
dren. With the standard dosing schedule, nature of
outcome was not associated with the plasma concentra-
tions or AUC0–4 achieved for any of the four drugs stud-
ied. However, there was a trend of median (IQR) Cmax of
INH being lower in children with poor outcome [1.3
(0.7, 1.5) vs. 3.4 (1.8, 5.0) μg/mL, p = 0.05].
Only confirmation of Mycobacterium tuberculosis was
associated with the outcome, with children with poor
outcome having a higher percentage of confirmed cases
(55.6% vs. 16.4%, p = 0.01) (Table 5). A multivariate lo-
gistic regression model showed that there was no associ-
ation of 2-hour plasma concentration of INH, RIF, PZA
and EMB with poor outcome, when adjusted for age,
weight for age and height for age z score and BCG vac-
cination status.
In the second group, three (4.9%) children were ad-
ministered category II ATT due to worsening or non-
improvement of symptoms, one (1.6%) child had relapse
of disease. There was only one death in a child with dis-
seminated TB and severe malnutrition. Three (4.9%)
children had developed features of hepatitis in this
group. Even with the increased dosage schedule, concen-
trations of the four drugs studied were not associatedwith the outcome of treatment. In this group, children
with lower weight and BMI z score had poorer outcome
(Table 5).Discussion
The current study, conducted in 127 children with tu-
berculosis, observed that most of the children had low
levels of at least one of the four drugs, the plasma levels
of isoniazid and ethambutol were suboptimal in majority
of children enrolled. With the revised dosage, concentra-
tions of both isoniazid and rifampicin increased, though
the change was not statistically significant in case of ri-
fampicin. We did not observe an association between
low plasma drug concentrations and poor outcome.
There was no effect of malnutrition on 2-hour concen-
trations, Cmax, Tmax, and AUC0–4 of isoniazid, rifampi-
cin, pyrazinamide and ethambutol in either of the two
dosing schedules used.
Multiple time point sampling as in conventional
pharmacokinetic studies is challenging in children as
there are concerns regarding parental consent, ethical
issues and collection of samples. A limited sampling ap-
proach at four time points was adopted in this study.
This strategy had been validated for rifampicin in an
earlier study from the same institute conducted in
adults to study the absorption phase [26]. Though it
was not possible to comment on parameters like half-
life and volume of clearance, the absorption spectrum
could be well studied.
The assays used for measurement of serum or plasma
drug concentrations in the previous studies on pharmaco-
kinetics of anti-tubercular drugs in children have been
varied and hence, the comparison of results obtained is
challenging. Of various assays to measure the plasma drug
levels, LC-MS/MS is the most sophisticated and sensitive,
only a few studies in children with tuberculosis have used
this assay [7,8]. In the current study, the plasma concen-
trations of all the four first line anti-tubercular drugs were
measured simultaneously by LC-MS/MS. This allowed a
high throughput and sensitive assay.
The plasma levels of the anti-tubercular drugs have been
evaluated both for intermittent dosing, [10,16,27,28] and
daily schedules [7,8,29-31]. There are differences in the
formulations used in various studies. Some of the studies
used individual, separate tablets for each drug studied,
[16,30-32] while in many other studies fixed dose formula-
tions of isoniazid, rifampicin and pyrazinamide were used
[7-9,29,33]. The current study reports the pharmacoki-
netic details of isoniazid, rifampicin, pyrazinamide as well
as ethambutol in Indian children, after daily dosing of the
medicines using fixed dose formulations of isoniazid, ri-
fampicin and pyrazinamide along with separate tablets of
ethambutol.
Table 5 Factors affecting outcome of therapy in children with at least six months of follow-up on ATT





p value Good outcome n = 44 Poor outcome n = 17 p value
2-hr plasma isoniazid concentration,
μg/mL
0.4 (0.2, 0.8) 0.5 (0.2, 0.8) 0.9 2.3 (1.2, 3.9) 1.7 (1.3, 2.8) 0.2
2-hr plasma rifampicin concentration,
μg/mL
8.7 (5.4, 11.9) 9.7 (3.9, 11.6) 0.8 9.5 (5.3, 21.2) 11.3 (5.7, 15.2) 0.9
2-hr pyrazinamide concentration,
μg/mL
40.4 (34.8, 46.9) 44.2 (38.4, 53.1) 0.7 39.8 (35.0, 44.7) 41.4 (34.4, 47.8) 0.8
2-hr ethambutol concentration,
μg/mL
0.7 (0.4, 1.5) 0.6 (0.5, 0.9) 0.4 2.5 (1.7, 3.7) 3.2 (2.2, 4.8) 0.2
Cmax isoniazid, μg/mL 3.4 (1.8, 5.0) 1.3 (0.7, 1.5) 0.05 3.2 (2.0, 4.7) 3.5 (1.8, 5.2) 0.6
Cmax rifampicin, μg/mL 10.3 (6.8, 13.9) 11.5 (7.8, 14.3) 0.9 10.4 (7.7, 14.0) 12.8 (6.6, 15.3) 0.5
Cmax pyrazinamide, μg/mL 50.1 (39.2, 67.5) 52.8 (43.5, 68.5) 0.8 46.7 (40.4, 52.6) 43.4 (38.4, 53.9) 0.5
Cmax ethambutol, μg/mL 1.1 (0.7, 2.1) 1.2 (0.5, 1.9) 0.8 3.3 (2.3, 4.1) 3.7 (2.3, 4.9) 0.4
AUC0–4 isoniazid, μg/mL*hr 1.3 (0.7, 2.4) 1.9 (1.5, 3.3) 0.2 7.9 (4.2, 13.2) 5.9 (4.5, 10.1) 0.3
AUC0–4 rifampicin, μg/mL*hr 27.9 (19.1, 36.1) 30.2 (23.5, 34.1) 0.8 25.3 (16.6, 60.7) 30.6 (21.7, 44.1) 0.8
AUC0–4 pyrazinamide, μg/mL*hr 159.9 (111.8, 207.0) 155.3 (125.3, 210.9) 0.9 137.8 (123.6, 158.3) 133.7 (121.4, 151.6) 0.5
AUC0–4 ethambutol, μg/mL*hr 2.5 (1.5, 5.5) 2.1 (1.4, 3.7) 0.5 7.7 (4.9, 10.7) 10.0 (5.9, 10.9) 0.5
WAZ at baseline −1.8 (−2.8, -1.1) −1.9 (−3.2, -1.7) 0.3 −1.3(−1.9, -0.6) −1.9 (−2.3, -1.8) 0.007
HAZ at baseline −1.5 (−2.1, -0.2) −1.2 (−1.9, -0.2) 0.8 −1.1 (−2.3, -0.2) −1.5 (−1.9, -0.8) 0.5
Received BCG, n (%) 42 (76.4) 6 (66.7) 0.7 31 (70.4) 11 (64.7) 0.7
Mycobacterium confirmed, n (%) 9 (16.4) 5 (55.6) 0.01 8 (18.6) 4 (23.5) 0.7
Diagnosis, n (%) 0.9 0.5
Progressive pulmonary disease 30 (56.6) 5 (55.6) 17 (38.6) 10 (58.8)
Pleural effusion 7 (13.2) 1 (11.1) 1 (2.3) 1 (5.9)
Disseminated 16 (30.2) 3 (33.3) 2 (4.5) 1 (5.9)
Osteoarticular 0 0 9 (20.5) 2 (11.8)
Peripheral lymphadenopathy 0 0 15 (34.1) 3 (17.6)
Values are median (IQR) unless specified, AUC: area under curve, WAZ: weight for age z score, HAZ: height for age z score, BCG: Bacillus Calmette–Guérin,
IQR: interquartile range, Cmax: maximum concentration.
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Several studies have reported low 2-hour concentration
or low Cmax of isoniazid in large proportion of children
with doses of around 5 mg/kg/day, though not in the
proportions observed in the current study. In earlier
studies up to 83% children have been reported to have a
suboptimal plasma concentration of isoniazid. [8,29]
While some authors have reported low levels in only 12-
14% of children studied [16,34].
Thee et al. reported low Cmax in half of the children
following a dose of 5 mg/kg of isoniazid, but in none
after dose of 10 mg/kg in children younger than two
years [33]. Recent simulation studies have showed that
higher doses lead to increased Cmax and isoniazid expos-
ure [35,36]. A study on 20 low birth weight infants dem-
onstrated that though adequate Cmax was achieved at a
dose of 10 mg/kg INH, elimination was reduced in
younger and smaller infants, thus raising a note of cau-
tion against using higher doses in this age group [37].Our study showed a significantly higher increase in Cmax
and AUC0–4 in younger children (less than five years),
when the revised doses were used. Hence the impact of
increasing the dose may be different in children accord-
ing to age groups and should be taken into account
while hiking the INH doses.
Acetylator status predicted the isoniazid exposure in
our cohort of children, fast acetylators having a lower 2-
hour level, Cmax and AUC0–4. This corroborates with the
findings of other researchers who also observed an asso-
ciation of lower isoniazid concentrations with fast acety-
lator phenotype [6,8]. Acetylation status varies according
to the ethnicity of populations. India has a population of
diverse gene pool varying with geographical regions [38].
There have been dissimilar reports from different parts
of India on the acetylator status of Indian population,
determined phenotypically and genotypically. Studies
from south India have established a predominance of
slow acetylators up to 74% of the population [39]. A
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in south Indian children, determined by estimation of sal-
ivary INH levels [16]. However other studies from north
Indian adult population have reported lower proportion of
slow acetylators, [40-42] ranging from 14.5% to 35.4%.
The distribution of acetylator phenotype in the current
study, with 81.2% fast acetylators, matches that of north
Indian population. Since acetylator status is an important
factor in the plasma concentration of INH achieved by a
person, intra and inter population differences will have an
impact on determining the doses needed for a particular
population and the guidelines issued by any program.
Increasing the dose has significantly improved the
plasma concentrations in our study, providing support-
ive evidence to the revised dosing schedule of WHO.
But the number of children with low two hour levels still
remain unacceptably high (68.2%), factors other than
just increasing the dose must be sought to explain this.
Also some caution and more studies may be warranted
while using the higher dose in younger children, as
shown in our study that younger children may achieve
better plasma concentrations of the drug. Recent WHO
guidelines have recommended isoniazid in the range of
7–15 mg/kg mainly to facilitate ease of administration
with the currently available FDCs [43].
Rifampicin
Several studies have raised concern regarding inadequate
exposure of rifampicin after a dose of around 10 mg/kg.
Seth et al. demonstrated a Cmax of 3.3- 3.8 μg/mL after
an average dose of 12 mg/kg of rifampicin [44]. In recent
studies with doses of around 10 mg/kg up to 90% chil-
dren had sub-therapeutic maximum concentrations of
rifampicin [7,16,29].
Using the revised WHO dosing schedule, Thee et al.
demonstrated that Cmax and AUC were significantly aug-
mented when dose of rifampicin was increased from 10 to
15 mg/kg. A dose of 15 mg/kg led to only three out of
eleven children having suboptimal peak concentration of
rifampicin [33]. In our study the concentrations of rifam-
picin did increase with dose, but not significantly, neither
did the number of children with low two hour levels vary.
Inspite of initial concerns, studies have now documented
that the bioavailability from fixed dose combinations and
single, separate formulations are equivalent [45]. Hence,
the use of fixed dose combinations in our study, may not
have contributed substantially to the low levels of con-
cerned drugs. Again there may be other factors like mal-
absorption, drug-interactions, efflux proteins, contributing
to the low levels other than just inadequate dose.
Pyrazinamide
There have been few reports in children regarding low
levels of pyrazinamide. Approximately one-thirds ofchildren receiving 30–33 mg/kg of pyrazinamide have
been reported to have low peak concentrations [9,10,16,
29, 30,46].
Our study demonstrated that concentrations achieved
by administering pyrazinamide above 30 mg/kg were ad-
equate and very few children had inadequate 2-hour
levels of pyrazinamide.
Ethambutol
Data regarding pharmacokinetics of ethambutol in chil-
dren is limited globally. Various authors have reported low
levels of plasma ethambutol concentrations [10,47,48], the
average doses ranged from 15 mg/kg to 25 mg/kg. In view
of more than half (55.9%) of the children in our study hav-
ing low 2-hour levels of ethambutol at a mean dose of
21.7 mg/kg, consideration may be given to increasing the
dose, albeit keeping in mind the possible toxicities. How-
ever, additional pharmacokinetic studies are needed to
garner further evidence before any suggestions can be
made.
Effect of malnutrition
In our study, we did not observe any effect of malnutri-
tion on 2 hour concentrations, Cmax, Tmax, and AUC0–4
of isoniazid, rifampicin, pyrazinamide or ethambutol,
even with enhanced dosing. There are contrasting re-
ports of influence of nutritional status on exposure of
anti-tubercular drugs in children. Some earlier studies
on isoniazid and rifampicin reported that serum concen-
trations of these drugs were higher in malnourished chil-
dren [49].
Other studies in children with poor nutritional status
have suggested that bioavailability of anti-tubercular
drugs, especially rifampicin and pyrazinamide is lower in
malnutrition [16,50]. On the other hand, similar to our
results, few studies have reported absence of effect of
malnutrition on pharmacokinetics of anti- tubercular
drug levels [8,10,27,33,51,52].
There are various pathophysiological changes associ-
ated with malnutrition which may affect different as-
pects of drug pharmacokinetics, it is difficult to predict
the result of interplay of the various effects. This study
and the previous studies have estimated the total plasma
concentrations; it may be worthwhile to determine the
free drug concentrations in plasma as well as the intra-
cellular drug concentrations, the latter may particularly
be relevant as the pathogen is intracellular.
Correlation with treatment response
The outcome of tuberculosis in this cohort of children
was not influenced by the levels of anti-tubercular drugs
studied. However, there was a trend of median Cmax of
INH being lower in children with poor outcome at the
dose of 5 mg/kg. The cut off levels for optimal plasma
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rived from adult healthy volunteers studied under con-
trolled environment and validated at National Jewish
Medical and Research Center by Peloquin et al. [24].
These two hour cut-off values have since been widely
used worldwide by various researchers. But the optimal
concentrations required for effective therapy and hence,
cure of tuberculosis in children are not exactly known as
there are very few studies which have tried to associate
dose and serum concentrations of anti-tubercular drugs
with successful outcome of therapy.
In a study on Indian children on intermittent ATT,
unfavorable treatment outcome was found to be associ-
ated with lower isoniazid and rifampicin exposure [16].
A South African study primarily designed to assess the
difference in serum concentration of rifampicin in HIV
infected and uninfected children, demonstrated no asso-
ciation between weight gain or chest X-ray clearance
and any of the pharmacokinetic parameters of rifampicin
[7]. In addition to the drug concentrations, the body’s
immune system is likely to play a major role in tackling
the tuberculosis disease. Also the drugs have to target
the mycobacteria, most of which are intracellular, it may
be important to study the intracellular drug concen-
trations as well. Synergistic action of pyrazinamide with
rifampicin, isoniazid with ethambutol may compensate
for the low levels of one drug [53]. This may explain the
observation of acceptable outcomes in a scenario where
most of the anti-tubercular drugs showed low levels of
anti-tubercular drugs. However, there may be an effect
on long-term likelihoods of relapse; this aspect has not
been studied.
Interestingly, proportion of unfavourable outcome was
higher in children receiving the increased doses of ATT.
This group had higher numbers of children with extra-
pulmonary disease and had lower weight-for-age Z
scores than the group receiving lower doses; these may
have affected the response to therapy.
Strengths of this study include the use of a highly sen-
sitive assay for simultaneously estimating the plasma
concentrations of all 4 first line anti-tubercular drugs in
children. We have assessed the drug levels after modify-
ing the doses of isoniazid and rifampicin. The present
study also described the pharmacokinetics of ethambutol
in Indian children for which data are not available in
published literature. Also the revised dosages of isonia-
zid and rifampicin have been evaluated in the Indian
children for the first time, enabling us to assess the effi-
cacy of this regimen. We have also reported outcomes in
the enrolled children.
The limitations of the study include the inability to
evaluate pharmacokinetic details like half-life, rate of
clearance, due to the truncated sampling strategy followed
and use of 2-hour plasma concentration as a measure ofoptimal dose. The limited numbers of children in each of
the treatment sub-groups complicates the assessment of
association of outcome with plasma concentrations of the
drugs.Conclusion
The results of this study have led credence to the concern
that doses used in children were inadequate leading to in-
adequate plasma concentrations of isoniazid, rifampicin
and ethambutol. Increasing the dose of isoniazid seems to
have beneficial effects on plasma concentration achieved.
But augmenting the dose of rifampicin has failed to sig-
nificantly alter the concentrations achieved or number of
children with low two hour levels. Malnutrition was not
associated with low plasma concentrations of any of these
drugs. No relationship was found between drug concen-
tration and treatment response, even in augmented doses.
We may have to be cautious while increasing the doses
and strive to asses any other factors which may be influen-
cing the drug concentrations and treatment outcomes in
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